

Figure 403: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients worsened – grades 1 and 2 pressure ulcers




Figure 404: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients worsened – grades 2 pressure ulcers





Figure 405: Topical ointment with petrolatum versus petrolatum (base component) – mortality



1.2.7.12 Zinc oxide versus streptokinase-streptodornase

Figure 406: Zinc oxide versus streptokinase-streptodornase – median percentage reduction in ulcer area




Figure 407: Zinc oxide versus streptokinase-streptodornase – proportion of patients with an infection




Figure 408: Zinc oxide versus streptokinase-streptodornase – proportion of patients with skin reaction





Figure 409: Zinc oxide versus streptokinase-streptodornase – mortality



I.2.7.13 Oxyquinoline versus A&D treatment

Figure 410: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (all grades)




Figure 411: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (grade I)



Figure 412: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (grade II)




Figure 413: Oxyquinoline versus A&D treatment – proportion of ulcers improved on day 15 (grade I)




Figure 414: Oxyquinoline versus A&D treatment – proportion of ulcers improved on day 22 (grade II)




Figure 415: Oxyquinoline versus A&D treatment – proportion of ulcers not changed on day 15 (grade I)




Figure 416: Oxyquinoline versus A&D treatment – proportion of ulcers not changed on day 22 (grade II)




Figure 417: Oxyquinoline versus A&D treatment – proportion of ulcers worsened on day 15 (grade I)




Figure 418: Oxyquinoline versus A&D treatment – proportion of ulcers worsened on day 22 (grade II)




Figure 419: Oxyquinoline versus A&D treatment – mean days to complete healing (all grades)




Figure 420: Oxyquinoline versus A&D treatment – mean days to complete healing (grade I)





Figure 421: Oxyquinoline versus A&D treatment – mean days to complete healing (grade II)



I.2.7.14 Ethoxy-diaminoacridine plus nitrofuazone versus honey

Figure 422: Ethoxy-diaminoacridine plus nitrofuazone versus honey – proportion of ulcers completely healed




Figure 423: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mean percentage reduction in PUSH score




Figure 424: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mean percentage reduction in ulcer size




Figure 425: Ethoxy-diaminoacridine plus nitrofuazone versus honey – proportion of people with treatment-related adverse events





Figure 426: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mortality



1.2.7.15 Povidone-iodine versus hydrocolloid

Figure 427: Povidone-iodine versus hydrocolloid – proportion of patients completely healed




Figure 428: Povidone-iodine versus hydrocolloid – mean speed of healing (mm²/day)




Figure 429: Povidone-iodine versus hydrocolloid – proportion of patients with hypergranulation






Figure 430: Povidone-iodine versus hydrocolloid – mortality



I.2.7.16 Povidon-iodine vs. hydrogel

Figure 431: Povidone-iodine versus hydrogel – mean cm²/day to healing



I.2.7.17 Cadexomer iodine vs. standard treatment

Figure 432: Cadexomer iodine versus standard treatment – proportion of ulcers reduced > 50%




Figure 433: Cadexomer iodine versus standard treatment – mean percentage reduction in ulcer area




Figure 434: Cadexomer iodine versus standard treatment – mean cm² reduction in ulcer area





Figure 435: Cadexomer iodine versus standard treatment – mortality



I.2.7.18 Silver sulfazidine cream vs. silver dressing

Figure 436: Silver sulfazidine cream versus silver dressing – mean percentage reduction in ulcer area




Figure 437: Silver sulfazidine cream versus silver dressing – proportion of people with treatment-related adverse events





Figure 438: Silver sulfazidine cream versus silver dressing – mortality



I.2.7.19 Resin salve vs. hydrofibre

Figure 439: Resin salve versus hydrofibre – proportion of patients completely healed




Figure 440: Resin salve versus hydrofibre – proportion of ulcers completely healed




Figure 441: Resin salve versus hydrofibre – proportion of ulcers improved




Figure 442: Resin salve versus hydrofibre – proportion of ulcers worsened



Figure 443: Resin salve versus hydrofibre – proportion of patients with allergic skin reactions






Figure 444: Resin salve versus hydrofibre – mortality




I.2.7.20 Antibiotic ointment vs. foam dressing

Figure 445: Antibiotic ointment versus foam dressing – proportion of patients completely healed



I.2.7.21 Insulin vs. standard treatment

Figure 446: Insulin versus standard treatment - mortality



I.2.7.22 Growth factors vs. placebo

Figure 447: Growth factors versus placebo – proportion of patients completely healed





Figure 448: Proportion of patients completely healed – growth factors versus placebo – inpatients – grade 3 and 4



Figure 449: Proportion of patients completely healed – growth factors versus placebo – nursing home patients – grade 2 and above



1.2.7.23 Topical growth factor – beta 3: 1.0ug/cm² versus placebo

Figure 450: Topical growth factor – beta 3: 1.0ug/cm² versus placebo – proportion of people with pressure ulcers completely healed





Figure 451: Topical growth factor – beta 3: 1.0ug/cm² versus placebo – mortality



I.2.7.24 Topical growth factor – beta 3: 2.5ug/cm² versus placebo

Figure 452: Topical growth factor – beta 3: 2.5ug/cm² versus placebo





Figure 453: Topical growth factor – beta 3: 2.5ug/cm² versus placebo



I.2.7.25 Topical growth factor – beta 3: 1.0g/cm² versus 2.5g/cm²

Figure 454: Topical growth factor – beta 3: 1.0g/cm² versus 2.5g/cm² – proportion of patients completely healed





Figure 455: Topical growth factor – beta 3: 1.0g/cm² versus 2.5g/cm² – mortality



I.2.7.26 Nerve growth factor (2.5 S murine) versus placebo

Figure 456: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients completely healed (foot ulcers)




Figure 457: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients improved by 3 or more grades (foot ulcers)




Figure 458: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients improved by 2 grades (foot ulcers)




Figure 459: Nerve growth factor (2.5 S murin) versus placebo – proportion of patients improved by 1 grade (foot ulcers)




Figure 460: Nerve growth factor (2.5 S murin) versus placebo – mean mm² reduction in ulcer area (foot ulcers)




Figure 461: Nerve growth factor (2.5 S murin) versus placebo – mean mm2 reduction in ulcer area (foot ulcers) – grade 2 and above




Figure 462: Nerve growth factor (2.5 S murin) versus placebo – proportion of people with treatment-related adverse events





Figure 463: Nerve growth factor (2.5 S murin) versus placebo – mortality



I.2.7.27 Recombinant platelet-derived growth factor (100µg/ml) versus placebo

Figure 464: Recombinant platelet-derived growth factor (100µg/ml) versus placebo – proportion of patients completely healed






Figure 465: Recombinant platelet-derived growth factor (100µg/ml) versus placebo – mortality



I.2.7.28 Recombinant platelet-derived growth factor: 100µg/ml versus 300µg/ml

Figure 466: Recombinant platelet-derived growth factor: 100µg/ml versus 300µg/ml – proportion of patients completely healed



I.2.7.29 Recombinant platelet-derived growth factor (300µg/ml) versus placebo

Figure 467: Recombinant platelet-derived growth factor (300µg/ml) versus placebo – proportion of patients completely healed



I.2.7.30 Granulo-macrophage/colony-stimulating factor (2.0µg/cm²) versus placebo

Figure 468: Granulo-macrophage/colony-stimulating factor (2.0µg/cm²) versus placebo – proportion of patients completely healed (after 1 year)




Figure 469: Granulo-macrophage/colony-stimulating factor (2.0µg/cm²) versus placebo – proportion of patients worsened (after 1 year)




Figure 470: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus placebo – mean percentage reduction in ulcer area





Figure 471: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus placebo –



1.2.7.31 Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus basic fibroblast growth factor (5.0g/cm²)

Figure 472: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus basic fibroblast growth factor (5.0g/cm²) – proportion of patients completely healed (after 1 year)




Figure 473: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus basic fibroblast growth factor (5.0g/cm²) – proportion of patients worsened (after 1 year)




Figure 474: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus basic fibroblast growth factor (5.0g/cm²) – mean percentage reduction in ulcer area





Figure 475: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus basic fibroblast growth factor (5.0g/cm²) – mortality



1.2.7.32 Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²)

Figure 476: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – proportion of patients completely healed (after 1 year)



Figure 477: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – proportion of patients worsened (after 1 year)




Figure 478: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – mean percentage reduction in ulcer area





Figure 479: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – mortality



I.2.7.33 Basic fibroblast growth factor (5.0g/cm²) versus placebo

Figure 480: Basic fibroblast growth factor (5.0g/cm²) versus placebo – proportion of patients completely healed (after 1 year)




Figure 481: Basic fibroblast growth factor (5.0g/cm²) versus placebo – proportion of patients worsened (after 1 year)




Figure 482: Basic fibroblast growth factor (5.0g/cm²) versus placebo – mean percentage reduction in ulcer area





Figure 483: Basic fibroblast growth factor (5.0g/cm²) versus placebo – mortality



I.2.7.34 Basic fibroblast growth factor (5.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²)

Figure 484: Basic fibroblast growth factor (5.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – proportion of patients completely healed (after 1 year)




Figure 485: Basic fibroblast growth factor (5.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – proportion of patients worsened (after 1 year)




Figure 486: Basic fibroblast growth factor (5.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – mean percentage reduction in ulcer area





Figure 487: Basic fibroblast growth factor (5.0g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) – mortality



I.2.7.35 Granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) versus placebo

Figure 488: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) versus placebo – proportion of patients completely healed (after 1 year)



Figure 489: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) versus placebo – proportion of patients worsened (after 1 year)




Figure 490: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) versus placebo – mean percentage reduction in ulcer area





Figure 491: Granulo-macrophage/colony-stimulating factor (2.0g/cm²) and basic fibroblast growth factor (5.0g/cm²) versus placebo – mortality



I.2.7.36 Recombinant platelet-derived growth factor (100µg/g) versus placebo

Figure 492: Recombinant platelet-derived growth factor (100µg/g) versus placebo – proportion of patients completely healed




Figure 493: Recombinant platelet-derived growth factor (100µg/g) versus placebo – proportion of patients ≥ 90% healed




Figure 494: Recombinant platelet-derived growth factor (100µg/g) versus placebo – proportion of patients with osteomyelitis




Figure 495: Recombinant platelet-derived growth factor (100µg/g) versus placebo – proportion of patients with an infection



Figure 496: Recombinant platelet-derived growth factor (100µg/g) versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis





Figure 497: Recombinant platelet-derived growth factor (100µg/g) versus placebo – mortality



1.2.7.37 Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo

Figure 498: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo – proportion of patients completely healed




Figure 499: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo – proportion of patients ≥ 90% healed




Figure 500: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo – proportion of patients with osteomyelitis




Figure 501: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo – infection




Figure 502: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo – proportion of patients with sepsis





Figure 503: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo – Proportion of patients with adverse events other than osteomyelitis, infection and sepsis



Figure 504: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g alternated with placebo – mortality



I.2.7.38 Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g

Figure 505: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g – proportion of patients completely healed



Figure 506: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g – proportion of patients ≥ 90% healed




Figure 507: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g – proportion of patients with osteomyelitis




Figure 508: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g – proportion of patients with an infection





Figure 509: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g – proportion of patients with adverse events other than osteomyelitis, infection and sepsis



Figure 510: Recombinant platelet-derived growth factor: 100µg/g versus 300µg/g – mortality



1.2.7.39 Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo

Figure 511: Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo – proportion of patients completely healed



Figure 512: Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo – proportion of patients ≥ 90% healed




Figure 513: Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo – proportion of patients with osteomyelitis




Figure 514: Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo – proportion of patients with an infection




Figure 515: Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo – proportion of patients with sepsis




Figure 516: Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis





Figure 517: Recombinant platelet-derived growth factor (300µg/g) alternated with placebo versus placebo – mortality



1.2.7.40 Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g

Figure 518: Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g – proportion of patients completely healed




Figure 519: Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g – proportion of patients ≥ 90% healed




Figure 520: Recombinant platelet-derived growth factor: 300µg/g alternated with placebo versus 300µg/g – proportion of patients with osteomyelitis

